State and territory governments, in conjunction with the Therapeutic Goods Administration (TGA), will determine which patient groups will receive access to medicinal cannabis products and what medicinal cannabis products can be manufactured.


The Commonwealth Department of Health, in conjunction with state and territory governments, has helped coordinate the development new clinical guidance documents for prescribers of medicinal cannabis products for treating chemotherapy-induced nausea and vomiting, epilepsy, multiple sclerosis, chronic non-cancer pain and palliative care, as well as an overview document.

For patients

For prescribers

A series of reviews of the evidence around the potential use of medicinal cannabis products in the following conditions is being undertaken, some of which are complete and available on the TGA website:

Find out more in the patient access section of this website or see the Access to medicinal cannabis products web page on the TGA website.